3//SEC Filing
Alpine ImmunoSciences, L.P. 3
Accession 0000899243-17-019053
CIK 0001626199other
Filed
Jul 25, 8:00 PM ET
Accepted
Jul 26, 5:00 PM ET
Size
6.8 KB
Accession
0000899243-17-019053
Insider Transaction Report
Form 3
Alpine Bioventures GP, LLC
10% Owner
Holdings
- 3,803,906
Common Stock
Alpine ImmunoSciences, L.P.
10% Owner
Holdings
- 3,803,906
Common Stock
Footnotes (2)
- [F1]Pursuant to that certain Agreement and Plan of Merger and Reorganization (the "Merger Agreement"), dated as of April 18, 2017, by and among the Issuer, Nautilus Merger Sub, Inc. and the corporation then known as Alpine Immune Sciences, Inc. ("Old Alpine"), each share of Old Alpine common stock was converted into 0.4969 shares of the Issuer's common stock (the "Exchange Ratio").
- [F2]Alpine BioVentures GP, LLC ("ABV LLC") is the general partner of the Reporting Person. Dr. Mitchell Gold and Dr. Jay Venkatesan are the Managing Partners of ABV LLC. Dr. Gold and Dr. Venkatesan are also limited partners of the Reporting Person. By virtue of their positions as Managing Partners of ABV LLC, Dr. Gold and Dr. Venkatesan may be deemed to have voting and investment power with respect to the shares held by the Reporting Person and as a result may be deemed to have beneficial ownership of such shares. Each of Dr. Gold and Dr. Venkatesan disclaims beneficial ownership of the shares held by the Reporting Person, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person, Dr. Gold or Dr. Venkatesan is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
Documents
Issuer
ALPINE IMMUNE SCIENCES, INC.
CIK 0001626199
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001628571
Filing Metadata
- Form type
- 3
- Filed
- Jul 25, 8:00 PM ET
- Accepted
- Jul 26, 5:00 PM ET
- Size
- 6.8 KB